Roche Looks To Fuel Early-stage Partnerships In China While Shunning Branded Generics
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Unlike many of its peers, Roche AG is not interested in developing a specific partnering strategy for China or other emerging markets, according to Joe McCracken, Roche's global head of business development and licensing. Instead, the Swiss pharma relies on a single global strategy that includes China as a key player, the exec told PharmAsia News Oct. 11 during an interview on the sidelines of the first BIO China conference in Shanghai
You may also be interested in...
Roche Global Head of Business Development & Licensing Joe McCracken On Searching For Innovative Deals In Asia: An Interview With PharmAsia News (Part 2 of 2)
Joe McCracken, global head of business development & licensing for Roche AG, has a unique perspective on dealmaking, filtered through the lens of a career that has spanned from biotech to Big Pharma, from the U.S. West Coast to Japan to Nutley, New Jersey.
Roche Global Head of Business Development & Licensing Joe McCracken On Searching For Innovative Deals In Asia: An Interview With PharmAsia News (Part 2 of 2)
Joe McCracken, global head of business development & licensing for Roche AG, has a unique perspective on dealmaking, filtered through the lens of a career that has spanned from biotech to Big Pharma, from the U.S. West Coast to Japan to Nutley, New Jersey.
Roche Global Head of Business Development & Licensing Joe McCracken On Searching For Innovative Deals In Asia: An Interview With PharmAsia News (Part 1 of 2)
Joe McCracken, global head of business development & licensing for Roche AG, has a unique perspective on dealmaking, filtered through the lens of a career that has spanned from biotech to Big Pharma, from the U.S. West Coast to Japan to Nutley, New Jersey.